These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15494603)

  • 21. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of paternal age at birth and the risk of breast cancer in offspring: a case control study.
    Choi JY; Lee KM; Park SK; Noh DY; Ahn SH; Yoo KY; Kang D
    BMC Cancer; 2005 Oct; 5():143. PubMed ID: 16259637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.
    Macis D; Maisonneuve P; Johansson H; Bonanni B; Botteri E; Iodice S; Santillo B; Penco S; Gucciardo G; D'Aiuto G; Rosselli Del Turco M; Amadori M; Costa A; Decensi A
    Breast Cancer Res Treat; 2007 Dec; 106(2):263-71. PubMed ID: 17260091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
    Duggan C; Marriott K; Edwards R; Cuzick J
    J Clin Oncol; 2003 Oct; 21(19):3588-93. PubMed ID: 14512389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
    Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
    J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen treatment and new-onset depression in breast cancer patients.
    Lee KC; Ray GT; Hunkeler EM; Finley PR
    Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
    Owusu C; Lash TL; Silliman RA
    Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.